These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36068712)

  • 1. Barriers to accessing sterile injecting equipment for people who inject drugs: An integrative review.
    Lawson E; Walthall H
    J Clin Nurs; 2023 Aug; 32(15-16):4502-4514. PubMed ID: 36068712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis.
    Aghaei AM; Gholami J; Sangchooli A; Rostam-Abadi Y; Olamazadeh S; Ardeshir M; Baheshmat S; Shadloo B; Taj M; Saeed K; Rahimi-Movaghar A
    Lancet Glob Health; 2023 Aug; 11(8):e1225-e1237. PubMed ID: 37474230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.
    Degenhardt L; Webb P; Colledge-Frisby S; Ireland J; Wheeler A; Ottaviano S; Willing A; Kairouz A; Cunningham EB; Hajarizadeh B; Leung J; Tran LT; Price O; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Grebely J
    Lancet Glob Health; 2023 May; 11(5):e659-e672. PubMed ID: 36996857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020).
    Palmateer N; Hamill V; Bergenstrom A; Bloomfield H; Gordon L; Stone J; Fraser H; Seyler T; Duan Y; Tran R; Trayner K; Biggam C; Smith S; Vickerman P; Hickman M; Hutchinson S
    Int J Drug Policy; 2022 Nov; 109():103872. PubMed ID: 36202039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I could take the judgment if you could just provide the service: non-prescription syringe purchase experience at Arizona pharmacies, 2018.
    Meyerson BE; Lawrence CA; Cope SD; Levin S; Thomas C; Eldridge LA; Coles HB; Vadiei N; Kennedy A
    Harm Reduct J; 2019 Sep; 16(1):57. PubMed ID: 31533730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the impact of global fund withdrawal on needle and syringe provision, cost and use among people who inject drugs in Tijuana, Mexico: a costing analysis.
    Cepeda JA; Burgos JL; Kahn JG; Padilla R; Meza Martinez PE; Segovia LA; Gaines T; Abramovitz D; Rangel G; Magis-Rodriguez C; Vickerman P; Strathdee SA; Martin NK
    BMJ Open; 2019 Jan; 9(1):e026298. PubMed ID: 30700490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Apparently, you can only be treated once": A qualitative study exploring perceptions of hepatitis C and access to treatment among people who inject drugs visiting a needle and syringe program.
    Fontaine G; Presseau J; Bruneau J; Patey AM; van Allen Z; Mortazhejri S; Høj SB; Hung JC; Grimshaw JM
    Int J Drug Policy; 2023 Nov; 121():104124. PubMed ID: 37451942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reviewing harm reduction for people who inject drugs in Asia: the necessity for growth.
    Stone KA
    Harm Reduct J; 2015 Oct; 12():32. PubMed ID: 26472335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - a scoping review of the qualitative evidence.
    Balsom CR; Farrell A; Kelly DV
    BMC Public Health; 2023 Jun; 23(1):1038. PubMed ID: 37259073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with sharing equipment among people who inject drugs: The role of community attachment in harm reduction and health promotion.
    Broady TR; Brener L; Caruana T; Cama E; Treloar C
    Drug Alcohol Rev; 2023 Mar; 42(3):561-568. PubMed ID: 36729689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of injecting among people who inject drugs: A systematic review and meta-analysis.
    Colledge S; Leung J; Larney S; Peacock A; Grebely J; Hickman M; Cunningham E; Trickey A; Stone J; Vickerman P; Degenhardt L
    Int J Drug Policy; 2020 Feb; 76():102619. PubMed ID: 31864107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "We don't need services. We have no problems": exploring the experiences of young people who inject drugs in accessing harm reduction services.
    Krug A; Hildebrand M; Sun N
    J Int AIDS Soc; 2015; 18(2 Suppl 1):19442. PubMed ID: 25724510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study.
    Akiyama MJ; Muller A; Huang O; Lizcano J; Nyakowa M; Riback L; Ross J; Bundi H; Kulabi ES; Mwangi AM; Musyoki H; Cherutich P; Kurth A
    Glob Public Health; 2022 Jun; 17(6):1016-1028. PubMed ID: 33689563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs.
    Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Turcotte MÈ; Bruneau J
    Am J Prev Med; 2020 Jun; 58(6):845-853. PubMed ID: 32444003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.
    MacArthur GJ; van Velzen E; Palmateer N; Kimber J; Pharris A; Hope V; Taylor A; Roy K; Aspinall E; Goldberg D; Rhodes T; Hedrich D; Salminen M; Hickman M; Hutchinson SJ
    Int J Drug Policy; 2014 Jan; 25(1):34-52. PubMed ID: 23973009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to needles and syringes and methadone maintenance therapy among people who inject drugs in Yangon, Myanmar: a qualitative study.
    Yee WL; Draper B; Myint KT; Min W; Htay H; O'Keefe D; Hellard M
    Harm Reduct J; 2022 Sep; 19(1):107. PubMed ID: 36175872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.